Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,598 | -2,629 | -356 | 752 | 1,094 |
| Depreciation Amortization | 153 | 108 | 105 | 108 | 102 |
| Accounts receivable | 148 | 651 | 539 | 579 | 411 |
| Accounts payable and accrued liabilities | 204 | -381 | -120 | -1,181 | -524 |
| Other Working Capital | 115 | 118 | 833 | -862 | 102 |
| Other Operating Activity | -1,257 | 311 | -450 | 613 | -632 |
| Operating Cash Flow | $-2,234 | $-1,822 | $552 | $9 | $553 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -227 | -149 | -54 | -3 | 1,046 |
| Net Acquisitions | N/A | N/A | N/A | N/A | 346 |
| Purchase Of Investment | -493 | -321 | -512 | -516 | -109 |
| Sale Of Investment | 1,069 | 26 | N/A | 6 | 30 |
| Other Investing Activity | 69 | -1,350 | 115 | 22 | 6 |
| Investing Cash Flow | $418 | $-1,794 | $-451 | $-491 | $1,320 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | -34 | -26 | -5 |
| Common Stock Issued | N/A | 5,750 | 150 | N/A | N/A |
| Other Financing Activity | 145 | 525 | -8 | -2 | 0 |
| Financing Cash Flow | $145 | $6,275 | $108 | $-28 | $-5 |
| Exchange Rate Effect | 40 | -260 | -215 | -154 | 61 |
| Beginning Cash Position | 4,518 | 2,119 | 2,124 | 2,788 | 859 |
| End Cash Position | 2,887 | 4,518 | 2,119 | 2,124 | 2,788 |
| Net Cash Flow | $-1,631 | $2,399 | $-5 | $-664 | $1,929 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,234 | -1,822 | 552 | 9 | 553 |
| Capital Expenditure | -227 | -149 | -54 | -3 | -422 |
| Free Cash Flow | -2,461 | -1,972 | 498 | 6 | 131 |